Theriva Biologics, Inc. financial data

Symbol
TOVX on NYSE
Industry
Pharmaceutical Preparations
Location
9605 Medical Center Drive, Suite 270, Rockville, MD
State of incorporation
NV
Fiscal year end
December 31
Former names
Synthetic Biologics, Inc. (to 10/12/2022), ADEONA PHARMACEUTICALS, INC. (to 2/17/2012), PIPEX PHARMACEUTICALS, INC. (to 10/16/2008), SHEFFIELD PHARMACEUTICALS INC (to 12/8/2006), SHEFFIELD MEDICAL TECHNOLOGIES INC (to 5/14/1997)
Latest financial report
10-K - Q4 2024 - Mar 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 278 % -34.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2.78M shares -83.8%
Common Stock, Shares, Outstanding 2.78M shares +305%
Entity Public Float 5.3M USD
Common Stock, Value, Issued 3K USD +200%
Weighted Average Number of Shares Outstanding, Basic 1.35M shares +109%
Weighted Average Number of Shares Outstanding, Diluted 1.35M shares +109%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 12M USD -15.9%
General and Administrative Expense 7.4M USD +3.88%
Operating Income (Loss) -26.3M USD -22.9%
Nonoperating Income (Expense) 693K USD -51.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -25.7M USD -28.3%
Income Tax Expense (Benefit) -1.64M USD -15.1%
Net Income (Loss) Attributable to Parent -3.3M USD +26.4%
Earnings Per Share, Basic -19 USD/shares +33.2%
Earnings Per Share, Diluted -19 USD/shares +33.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 11.6M USD -49.9%
Assets, Current 16.3M USD -40.6%
Property, Plant and Equipment, Net 270K USD -36%
Operating Lease, Right-of-Use Asset 1.27M USD -27.7%
Intangible Assets, Net (Excluding Goodwill) 17.4M USD -12.1%
Goodwill 0 USD -100%
Assets 35.4M USD -36%
Accounts Payable, Current 859K USD +11.6%
Employee-related Liabilities, Current 1.14M USD -24.6%
Accrued Liabilities, Current 3.37M USD +12.5%
Contract with Customer, Liability, Current 906K USD
Liabilities, Current 7.59M USD +12.6%
Contract with Customer, Liability, Noncurrent 906K USD
Deferred Income Tax Liabilities, Net 413K USD -79.2%
Operating Lease, Liability, Noncurrent 873K USD -39.5%
Liabilities 16.3M USD +4.92%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.18M USD -3781%
Retained Earnings (Accumulated Deficit) -335M USD -8.29%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 19.1M USD -48.4%
Liabilities and Equity 35.4M USD -36%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.88M USD +13%
Net Cash Provided by (Used in) Financing Activities -55K USD +96%
Net Cash Provided by (Used in) Investing Activities -8K USD +99.8%
Common Stock, Shares Authorized 350M shares 0%
Common Stock, Shares, Issued 2.81M shares +293%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -4.92M USD +13.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 11.7M USD -49.7%
Deferred Tax Assets, Valuation Allowance 11.3M USD -60.1%
Deferred Tax Assets, Gross 15.7M USD -52.9%
Operating Lease, Liability 1.41M USD -26.8%
Payments to Acquire Property, Plant, and Equipment 8K USD
Lessee, Operating Lease, Liability, to be Paid 1.63M USD -28.3%
Property, Plant and Equipment, Gross 1.21M USD -15.4%
Operating Lease, Liability, Current 539K USD +10.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 587K USD -11.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 672K USD +2.75%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 215K USD -36.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 368K USD -36.8%
Deferred Tax Assets, Operating Loss Carryforwards 9.71M USD -64.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 368K USD +3.08%
Depreciation, Depletion and Amortization 39K USD +21.9%
Deferred Tax Assets, Net of Valuation Allowance 4.38M USD -12.2%